Patents by Inventor Lawrence Friedhoff

Lawrence Friedhoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240390384
    Abstract: This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: December 27, 2023
    Publication date: November 28, 2024
    Inventor: Lawrence FRIEDHOFF
  • Publication number: 20240350510
    Abstract: A method for modulating tolerance to an opioid analgesic in a patient undergoing opioid analgesic therapy, the method comprising interrupting or administering concurrently with said opioid analgesic therapy an amount of ibogaine, ibogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof.
    Type: Application
    Filed: November 28, 2023
    Publication date: October 24, 2024
    Inventors: Emeline MAILLET, Lawrence FRIEDHOFF
  • Publication number: 20240024336
    Abstract: A method for modulating tolerance to an opioid analgesic in a patient undergoing opioid analgesic therapy, the method comprising interrupting or administering concurrently with said opioid analgesic therapy an amount of ibogaine, ibogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof.
    Type: Application
    Filed: September 13, 2023
    Publication date: January 25, 2024
    Inventors: Emeline MAILLET, Lawrence FRIEDHOFF
  • Publication number: 20230346795
    Abstract: This invention is directed to a method of treating alcohol dependence, including acute and post-acute withdrawal symptoms, comprising treating an alcohol dependent patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: May 9, 2023
    Publication date: November 2, 2023
    Inventors: Emeline MAILLET, Lawrence FRIEDHOFF
  • Publication number: 20230181604
    Abstract: Mitochondrially targeted antioxidants are used to prevent and treat severe inflammatory conditions including viral infection (such as COVID-19), systemic shock, trauma, burns, surgery associated with significant tissue damage, toxic damage, and damage associated with autoimmune reactions.
    Type: Application
    Filed: April 5, 2021
    Publication date: June 15, 2023
    Inventors: Maxim V. SKULACHEV, Roman ZINOVKIN, Alexander ANDREEV-ANDRIEVSKY, Maxim EGOROV, Elena KARGER, Anton PETROV, Lawrence FRIEDHOFF
  • Publication number: 20230038070
    Abstract: A composition containing amitochodrially-targeted antioxidant of the SkQ type and a polyacrylate, agarose, agar-agar orhyaluronic acid polymer useful for production of pharmaceutical, medicinal and cosmetic compositions having good stability. Such compositions may usefully also include lactic acid.
    Type: Application
    Filed: December 10, 2020
    Publication date: February 9, 2023
    Applicant: MITOTECH S.A.
    Inventors: Maxim SKULACHEV, Natalia MARMIY, Vadim TASHLITSKY, Lawrence FRIEDHOFF
  • Publication number: 20220023310
    Abstract: This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: September 21, 2021
    Publication date: January 27, 2022
    Inventor: Lawrence FRIEDHOFF
  • Publication number: 20210290634
    Abstract: A method for modulating tolerance to an opioid analgesic in a patient undergoing opioid analgesic therapy, the method comprising interrupting or administering concurrently with said opioid analgesic therapy an amount of ibogaine, ibogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof.
    Type: Application
    Filed: June 4, 2021
    Publication date: September 23, 2021
    Inventors: Emeline MAILLET, Lawrence FRIEDHOFF
  • Publication number: 20210145845
    Abstract: This invention is directed to a method of treating alcohol dependence, including acute and post-acute withdrawal symptoms, comprising treating an alcohol dependent patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: January 28, 2021
    Publication date: May 20, 2021
    Inventors: Emeline MAILLET, Lawrence FRIEDHOFF
  • Publication number: 20200085836
    Abstract: This invention is directed to a method of treating alcohol dependence, including acute and post-acute withdrawal symptoms, comprising treating an alcohol dependent patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: October 23, 2017
    Publication date: March 19, 2020
    Applicant: DemeRx, Inc.
    Inventors: Emeline Maillet, Lawrence Friedhoff
  • Publication number: 20200078367
    Abstract: This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: October 17, 2017
    Publication date: March 12, 2020
    Applicant: DemeRX, Inc.
    Inventor: Lawrence Friedhoff
  • Publication number: 20180280406
    Abstract: This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of about 50 ng/mL to about 180 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: October 10, 2017
    Publication date: October 4, 2018
    Applicant: DemeRx, Inc.
    Inventor: Lawrence Friedhoff
  • Publication number: 20170368074
    Abstract: This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 28, 2017
    Applicant: DemeRx, Inc.
    Inventors: Emeline Maillet, Lawrence Friedhoff
  • Publication number: 20170368073
    Abstract: This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 28, 2017
    Applicant: DemeRX, Inc.
    Inventor: Lawrence Friedhoff
  • Patent number: 9744174
    Abstract: A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: August 29, 2017
    Assignee: DEMERX, INC.
    Inventor: Lawrence Friedhoff
  • Patent number: 9591978
    Abstract: This invention is directed to a method for pre-screening an opioid-addicted patient to determine the patient's tolerance for a therapeutic dose of noribogaine.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 14, 2017
    Assignee: DEMERX, INC.
    Inventor: Lawrence Friedhoff
  • Patent number: 9561232
    Abstract: This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: February 7, 2017
    Assignee: DEMERX, INC.
    Inventors: Emeline Maillet, Lawrence Friedhoff
  • Patent number: 9561233
    Abstract: This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: February 7, 2017
    Assignee: DEMERX, INC.
    Inventor: Lawrence Friedhoff
  • Publication number: 20160271139
    Abstract: The disclosure provides a method to administer noribogaine to a human patient having drug addiction in dosages that provide efficacy without leading to any significant deleterious clinical signs.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 22, 2016
    Inventor: Lawrence Friedhoff
  • Patent number: 9345711
    Abstract: This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL (AUC/24 h) under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: May 24, 2016
    Assignee: DEMERX, INC.
    Inventor: Lawrence Friedhoff